title: [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
abstract: OBJECTIVE
  To investigate the effects of alendronate (Alen) on the prevention of systemic glucocorticoid-induced osteoporosis in patients with rheumatic diseases.
  
  
  METHODS
  140 patients suffering from rheumatic diseases, including systemic lupus erythematosus, polymyositis, dermatomyositis, and Sjögren's syndrome, with normal bone mineral density (BMD) and treated with oral glucocorticoids were randomly divided into 2 groups: Alen + calcium group (n = 74) receiving Alen 10 mg once a day and castrate D 600 0.6 g once a day for 24 weeks and control group (n = 66) receiving castrate D 600 0.6 g once a day for 24 weeks. The BMD and biomarkers of bone turnover were measured at baseline and 24 weeks after initiating glucocorticoid therapy.
  
  
  RESULTS
  After 24 weeks, the BMD values at lumbar spine, femoral neck, major trochanter, and Ward' s triangle increased by 6.1%, 6.3%, 3.3%, and 2.2% respectively compared with those at baseline (all P<0.05), however, those of the control group decreased by 8.7%, 9.1%, 7.7%, and 6.4% respectively (P<0.01, P<0.05), and the BMD levels at lumbar spine and femoral neck 24 weeks later of the Alen + calcium group were both higher than those of the control group (P<0.01, P<0.05). 24 weeks later the level of urine cross linked N-telopeptides of type I collagen (NTX) of the Alen + calcium group decreased (P<0.05), and the blood osteocalcin (BGP) of the Alen + calcium group increased, however, not significantly (P>0.05). There were no significant differences in serum AKP and BGP and urine NTX 24 weeks later between these 2 groups.
  
  
  CONCLUSIONS
  Improving BMD, alendronate plays an important role in the prevention of glucocorticoid-induced osteoporosis. However, calcium treatment alone fails to prevent the loss of bone.
authors.affiliation: Department of Rheumatology, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310009, China.
authors.forename: Qiao-hong
authors.initials: QH
authors.lastname: Wang
authors.forename: Hua-xiang
authors.initials: HX
authors.lastname: Wu
authors.forename: Yong-lu
authors.initials: YL
authors.lastname: Huang
authors.forename: Jing
authors.initials: J
authors.lastname: Xue
authors.forename: Xu-yan
authors.initials: XY
authors.lastname: Yang
authors.forename: Liang
authors.initials: L
authors.lastname: Zhu
authors.forename: Li-hong
authors.initials: LH
authors.lastname: Wen
mesh_terms: D000328:Adult; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D012216:Rheumatic Diseases / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D019386:Alendronate